BridgeBio reported that encaleret met primary and key secondary endpoints in a global Phase 3 study for autosomal dominant hypocalcemia type 1 (ADH1). Treated patients achieved normalization of serum and urine calcium in 76% of cases at 24 weeks versus 4% on conventional therapy, and parathyroid hormone correction rates improved markedly. BridgeBio described the therapy as generally well tolerated and said it plans regulatory filings next year. The result follows recent positive late‑stage data from the company and strengthens its rare‑disease franchise. The readout highlights the continued viability of precision medicines in small patient populations and the commercial opportunity for targeted endocrine modulators in genetic conditions.